Table 5 Therapeutic strategies targeting the TGF-β pathway
From: Combination strategies to maximize the benefits of cancer immunotherapy
Therapeutic categories | Targets | Drugs |
|---|---|---|
Small molecules | TGF-βR1 | Galunisertib, vactosertib, BMS-986260, LY3200882; PF-06952229 |
Antibodies | Pan-TGF-β | Fresolimumab, SAR439459, NIS793 |
Glycoprotein-A repetitions predominant (GARP)- TGF-β1 | ABBV-151 | |
TGF-β1 and TGF-β2 | XPA-42-089 | |
Bi-specific antibodies | TGF-βRII and PD-L1 | Binstrafusp alfa |
TGF-βRII and CTLA4 | a-CTLA4-TGFβRIIecd | |
Antisense | TGF-β2 | Trabedersen |
Modified ACT | Dominant-negative TGF-βRII |  |